Navigation Links
Study finds post-transplant patients off steroids have fewer cardiovascular events
Date:5/7/2010

CINCINNATIPost-transplant patients who have been removed from a corticosteroid regimen have fewer cardiovascular events than those patients on steroids, increasing their graft survival rates and reducing early mortality, according to study results being presented this week by University of Cincinnati (UC) transplantation researchers.

Researchers with the division of transplantation and department of internal medicine are presenting the work at the American Transplant Congress (ATC), the annual meeting of the American Society of Transplantation, held May 1-5 in San Diego.

Corticosteroids are commonly given to post-transplant patients as part of an immunosuppressive regime to promote graft survival. But the steroids also cause harmful cardiovascular side effects such as increased blood pressure, cholesterol and weight gain, says Rita Alloway, PharmD, UC research professor of internal medicine. UC's transplant clinical research team has largely focused on reducing patient exposure to corticosteroids during post-transplantation treatment.

"Ten years ago, almost 80 percent of post-transplant kidney patients were discharged from the hospital on steroids," she says. "Now, according to United Network for Organ Sharing (UNOS) reports, less than 20 percent are discharged from the hospital on steroids. We've effectively removed chronic steroids from the immunosuppressive regimen while maintaining similar graft survival outcomes."

In work led by UC research assistant professor of surgery Adele Rike Shields, PharmD, researchers are now able to show patients removed from a steroid treatment have decreased cardiovascular events after transplant, in addition to their lowered side effects.

Shields evaluated acute graft rejection and graft loss in 630 kidney transplant patients withdrawn from corticosteroids. She found the risk factors in the corticosteroid-withdrawn kidney transplant population are similar to those traditionally defined under conventional immunosuppression with steroids.

"With the summation of 10 years of work, we've been able to show that patients off corticosteroids have the same graft-function outcomes as patients on corticosteroids," says Alloway. "In addition, the patients off corticosteroids benefit from fewer cardiovascular events."

UC researchers are also presenting the results of continued studies on use of the cancer drug bortezomib in solid organ transplant recipients. Altogether, 10 abstracts on UC-led bortezomib work will be featured at the meeting.

In a study published in the December 2008 issue of Transplantation, UC director of transplantation E. Steve Woodle, MD, and his colleagues showed bortezomib, a cancer drug commonly used to treat cancer of the plasma cells, is effective in treating rejection episodes caused by antibodies that attack transplanted kidneys.

Now, says Alloway, UC is presenting data from the next logical series of studies on the drug's use in transplantation, including its effect on both late and early acute rejection and the desensitization of patients with high antibody levels pre-transplant.

In work presented by transplant pharmacy fellow Carlin Walsh, PharmD, investigators demonstrated the ability of bortezomib to significantly reduce the level of donor-specific antibodies when prior therapies have failed. Walsh received a Young Investigator Award from the American Society of Transplantation for the desensitization studies with bortezomib.

UC researchers are also reporting results of shared protocols on the bortezomib treatment for antibody-mediated rejection. After presenting their bortezomib findings at the 2009 ATC, UC researchers created the START collaborative to share standard of care treatment protocols for bortezomib therapies. Through the collaborative, transplant centers worldwide have requested this information to treat individual patients with a variety of solid organ transplant types.

"The information shared from this partnership represents an international collaborative experience of treating this unmet need in transplantation that inevitably results in graft loss," says Alloway. "Because transplant centers may have one to five antibody-mediated cases a year, it's difficult to assess a potential new treatment. But when you are able to share every center's cases together in one report, it's easier to identify trends that support definitive design of future controlled trials."


'/>"/>

Contact: Katy Cosse
kathryn.cosse@uc.edu
513-558-0207
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. NIH awards $2.7-million grant to Kent State to study cognitive impairment in heart failure patients
2. Mayo Clinic study reveals neighborhood asthma risks
3. Vitamin D Best Taken With Largest Meal of Day, Study Finds
4. Breast cancer metastasis increases after estrogen and progestin hormone therapies, MU study finds
5. Study Disputes Link Between Milk and Kidney Cancer
6. X-ray guided steroid injections effectively treat hamstring tendonitis, study suggests
7. Innovative Technology Developed at AGH Accurately Monitors Healthcare Professionals' Handwashing Practices, Study Shows
8. Study finds everolimus-eluting stent safer, more effective than paclitaxel-eluting stent
9. New Study Shows Parents How to Increase Their Kid's Success in Reading
10. Men With HPV at Higher Risk for HIV, Study Finds
11. Study finds cutting colonoscopy preparation from 2 days to 1 day just as effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology: